Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « MedMesh.i » - entrée « Clinical Trials as Topic »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Clinical Protocols < Clinical Trials as Topic < Clinical Trials, Phase II as Topic  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 101.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000076 (2020) Some drugs for COVID-19.
000115 (2020) Peter N. Taylor [Royaume-Uni] ; Lei Zhang [Royaume-Uni] ; Richard W J. Lee [Royaume-Uni] ; Ilaria Muller [Royaume-Uni] ; Daniel G. Ezra [Royaume-Uni] ; Colin M. Dayan [Royaume-Uni] ; George J. Kahaly [Allemagne] ; Marian Ludgate [Royaume-Uni]New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.
000286 (2019) Santos Casta Eda [Espagne] ; Dolores Martínez-Quintanilla [Espagne] ; José L. Martín-Varillas [Espagne] ; Noelia García-Casta Eda [Espagne] ; Belén Atienza-Mateo [Espagne] ; Miguel A. González-Gay [Espagne]Tocilizumab for the treatment of adult-onset Still's disease.
000397 (2019) Hajime Yoshifuji [Japon]Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
000449 (2019) Martijn J H. Doeleman ; Erik M. Van Maarseveen [Pays-Bas] ; Joost F. SwartImmunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis.
000544 (2019) Priya Hays [États-Unis] ; Caitlin Costello [États-Unis] ; Deepak Asudani [États-Unis]Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review.
000611 (2018) D. Camellino [Oman] ; C. DejacoUpdate on treatment of polymyalgia rheumatica.
000638 (2018) Nicolai Leuchten [Allemagne] ; Martin Aringer [Allemagne]Tocilizumab in the treatment of giant cell arteritis.
000672 (2018) Ali Berkant Avci [Turquie] ; Eugen Feist [Allemagne] ; Gerd Rüdiger Burmester [Allemagne]Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
000693 (2018) Francesca Bartoli [Italie] ; Sangmee Bae [États-Unis] ; Laura Cometi [Italie] ; Marco Matucci Cerinic [Italie] ; Daniel E. Furst [États-Unis]Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018.
000783 (2018) Frits Van Rhee [États-Unis] ; Peter Voorhees [États-Unis] ; Angela Dispenzieri [États-Unis] ; Alexander Foss [Norvège] ; Gordan Srkalovic [États-Unis] ; Makoto Ide [Japon] ; Nikhil Munshi [États-Unis] ; Stephen Schey [Royaume-Uni] ; Matthew Streetly [Royaume-Uni] ; Sheila K. Pierson [États-Unis] ; Helen L. Partridge [États-Unis] ; Sudipto Mukherjee [États-Unis] ; Dustin Shilling [États-Unis] ; Katie Stone [États-Unis] ; Amy Greenway [États-Unis] ; Jason Ruth [États-Unis] ; Mary Jo Lechowicz ; Shanmuganathan Chandrakasan [États-Unis] ; Raj Jayanthan [États-Unis] ; Elaine S. Jaffe [États-Unis] ; Heather Leitch [Canada] ; Naveen Pemmaraju [États-Unis] ; Amy Chadburn [États-Unis] ; Megan S. Lim ; Kojo S. Elenitoba-Johnson ; Vera Krymskaya [États-Unis] ; Aaron Goodman [États-Unis] ; Christian Hoffmann [Allemagne] ; Pier Luigi Zinzani [Italie] ; Simone Ferrero [Italie] ; Louis Terriou [France] ; Yasuharu Sato [Japon] ; David Simpson [Nouvelle-Zélande] ; Raymond Wong [Hong Kong] ; Jean-Francois Rossi [France] ; Sunita Nasta [États-Unis] ; Kazuyuki Yoshizaki [Japon] ; Razelle Kurzrock [États-Unis] ; Thomas S. Uldrick [États-Unis] ; Corey Casper [États-Unis] ; Eric Oksenhendler [France] ; David C. Fajgenbaum [États-Unis]International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
000857 (2018) K L Winthrop [États-Unis] ; X. Mariette [France] ; J T Silva [Espagne] ; E. Benamu [États-Unis] ; L H Calabrese [États-Unis] ; A. Dumusc [Suisse] ; J S Smolen [Autriche] ; J M Aguado [Espagne] ; M. Fernández-Ruiz [Espagne]ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
000964 (2017) Cosimo Bruni [Italie] ; Emanuela Praino [Italie] ; Yannick Allanore [France] ; Oliver Distler [Suisse] ; Armando Gabrielli [Italie] ; Florenzo Iannone [Italie] ; Marco Matucci-Cerinic [Italie]Use of biologics and other novel therapies for the treatment of systemic sclerosis.
000A21 (2017) Charles SchmidtThe struggle to do no harm in clinical trials.
000A24 (2017) Masashi Narazaki [Japon] ; Toshio Tanaka [Japon] ; Tadamitsu Kishimoto [Japon]The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
000A58 (2017) Francesco Muratore [Italie] ; Nicol Pipitone [Italie] ; Carlo Salvarani [Italie]Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.
000A60 (2017) Eleftherios Pelechas [Grèce] ; Paraskevi V. Voulgari [Grèce] ; Alexandros A. Drosos [Grèce]Sirukumab: a promising therapy for rheumatoid arthritis.
000B50 (2017) Christian Dejaco [Autriche] ; Elisabeth Brouwer [Pays-Bas] ; Justin C. Mason [Royaume-Uni] ; Frank Buttgereit [Allemagne] ; Eric L. Matteson [États-Unis] ; Bhaskar Dasgupta [Royaume-Uni]Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.
000B87 (2017) Ryota Sakai [Japon] ; Tsuneo Kondo [Japon] ; Takahiko Kurasawa [Japon] ; Eiko Nishi [Japon] ; Ayumi Okuyama [Japon] ; Kentaro Chino [Japon] ; Akiko Shibata [Japon] ; Yusuke Okada [Japon] ; Hirofumi Takei [Japon] ; Hayato Nagasawa [Japon] ; Koichi Amano [Japon]Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review.
000C14 (2017) Michele M. Luchetti [Italie] ; Devis Benfaremo [Italie] ; Armando Gabrielli [Italie]Biologics in Inflammatory and Immunomediated Arthritis.
000C15 (2017) Gianluca Moroncini [Italie] ; Giovanni Calogera [Italie] ; Devis Benfaremo [Italie] ; Armando Gabrielli [Italie]Biologics in Inflammatory Immune-mediated Systemic Diseases.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i -k "Clinical Trials as Topic" 
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i  \
                -Sk "Clinical Trials as Topic" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Clinical Trials as Topic
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021